Epigenomics AG (XTER:ECX)

€ 0.7 -0.088 (-11.17%) Market Cap: 490,000.00 Enterprise Value: -2.74 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 45/100

Q3 2022 Epigenomics AG Earnings Call Transcript
Nov 09, 2022

€6.6 (+4.76%)

Earnings
Q2 2022 Epigenomics AG Earnings Call Transcript
Aug 10, 2022

€9.4 (-0.63%)

Earnings
Q1 2022 Epigenomics AG Earnings Call Transcript
May 11, 2022

€9.98

Earnings
Q4 2021 Epigenomics AG Earnings Call Transcript
Mar 24, 2022

€11.3 (+2.73%)

Earnings
Q3 2021 Epigenomics AG Earnings Call Transcript
Nov 10, 2021

€17.6 (-2.00%)

Earnings
Q2 2021 Epigenomics AG Earnings Call Transcript
Aug 11, 2021

€23.48 (-5.32%)

Earnings
Q1 2021 Epigenomics AG Earnings Call Transcript
May 12, 2021

€23.96 (+1.01%)

Earnings
Q4 2020 Epigenomics AG Earnings Call Transcript
Mar 25, 2021

€52.96 (+10.88%)

Earnings
Epigenomics AG - Special Call Transcript
Oct 20, 2020
Q2 2020 Epigenomics AG Earnings Call Transcript
Aug 13, 2020

€403.27 (-1.53%)

Earnings
Epigenomics AG - Special Call Transcript
Aug 11, 2020
Q4 2019 and Preliminary Q1 2020 Epigenomics AG Earnings Call Transcript
Apr 29, 2020

€211.83 (+3.45%)

Earnings
Epigenomics AG - Special Call Transcript
Nov 21, 2019
Nine Months 2019 Epigenomics AG Earnings Call Transcript
Nov 19, 2019

€200.06 (+9.44%)

Earnings
Q2 2019 Epigenomics AG Earnings Call (German) Transcript
Aug 07, 2019

€213.06 (-16.22%)

Earnings
Q1 2019 Epigenomics AG Earnings Call Transcript
May 08, 2019

€284.84 (-2.86%)

Earnings
Full Year 2018 Epigenomics AG Earnings Call Transcript
Mar 27, 2019

€268.8 (+0.69%)

Earnings

Epigenomics AG - Special Call Transcript

Aug 11, 2020 / 01:30PM GMT

Release Date Price: €395.42

Transcript

Operator

Good afternoon, ladies and gentlemen, and welcome to the Epigenomics AG Study Results Conference Call. (Operator Instructions)

Let me now turn over the floor to your host, Mr. Frederic Hilke. Go ahead, please.

Frederic Hilke

Epigenomics AG - IR Officer

Thank you very much, Julia. Hello, and welcome to the conference call. Today, we will discuss the recent publication in the Journal of the National Cancer Institute titled Comparing the Cost Effectiveness of Innovative Colorectal Cancer Screening Tests. My name is Frederic Hilke. I'm the Investor Relations Manager for Epigenomics. With me here on the phone is the CEO of Epigenomics AG, Greg Hamilton; and Dr. Jorge Garces, Epigenomics President and Chief Scientific Officer.

Before I hand over the presentation to Greg, let me point out some of the usual legal information. The following presentation will contain expressly or implicitly certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.